Sparsentan shows mixed results in FSGS Phase 3 trial compared to irbesartan, revealing key benefits and trial design challenges.
Pharmacy benefit managers face new transparency rules under the 2026 federal law, reshaping drug negotiations and access for…
Early childhood may hold critical clues to reducing ADHD risk. Researchers track developmental risks from pregnancy through toddlerhood.
The 2026 cholesterol guideline expands therapy eligibility to over half of U.S. adults, highlighting new risk thresholds and…
Sleep deprivation can lead to decreased cognitive function and impaired motor skills, affecting individuals who work in high-pressure…
Narcolepsy treatment breakthrough as FDA approves Takeda's oral drug Orzeyful, offering the first therapy to target all type…
Sparsentan shows mixed results in FSGS Phase 3 trial compared to irbesartan, revealing key benefits and trial design…
Sparsentan FSGS treatment offers a new FDA‑approved option for focal segmental glomerulosclerosis, prompting clinicians to compare it with…
Journavx revenue surged as Vertex Pharmaceuticals reported $3.33 billion Q2 earnings, driven by the new acute pain drug’s…
Discover how ALK-positive lung cancer treatment is evolving with new inhibitors, improving survival for thousands of patients worldwide.
Biosimilars reduce drug costs by up to 70%, but patient access depends on insurance coverage and policy decisions.
